Economic Times | Encouraging Results on Gileads Sovaldi Zacks.com In the second study – a single-arm open-label phase II study (GS-US-334-0126: n=40) – patients suffering from established recurrent HCV infection after liver transplantation received up to 24 weeks of therapy with Sovaldi and ribavirin. Results ... Gilead's Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C ... Gilead's Sovaldi Shows Efficacy & Safety In Chronic Hepatitis C Patients Gilead’s Sovaldi® Demonstrates Efficacy and Safety Among Chronic ... |
